Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Accumulated Expenses (2019 - 2025)

Historic Accumulated Expenses for Summit Therapeutics (SMMT) over the last 7 years, with Q3 2025 value amounting to $27.0 million.

  • Summit Therapeutics' Accumulated Expenses rose 4635.49% to $27.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $27.0 million, marking a year-over-year increase of 4635.49%. This contributed to the annual value of $19.6 million for FY2024, which is 12263.46% up from last year.
  • According to the latest figures from Q3 2025, Summit Therapeutics' Accumulated Expenses is $27.0 million, which was up 4635.49% from $26.1 million recorded in Q2 2025.
  • Over the past 5 years, Summit Therapeutics' Accumulated Expenses peaked at $27.0 million during Q3 2025, and registered a low of $3.7 million during Q3 2023.
  • In the last 5 years, Summit Therapeutics' Accumulated Expenses had a median value of $8.8 million in 2023 and averaged $11.6 million.
  • Its Accumulated Expenses has fluctuated over the past 5 years, first tumbled by 6720.22% in 2023, then skyrocketed by 40566.5% in 2024.
  • Summit Therapeutics' Accumulated Expenses (Quarter) stood at $7.2 million in 2021, then surged by 48.17% to $10.7 million in 2022, then decreased by 17.64% to $8.8 million in 2023, then soared by 122.63% to $19.6 million in 2024, then soared by 38.29% to $27.0 million in 2025.
  • Its last three reported values are $27.0 million in Q3 2025, $26.1 million for Q2 2025, and $21.2 million during Q1 2025.